Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age
Abrocitinib has a manageable long-term safety profile. TEAEs of special interest were lower in adolescents and higher in the 65-years-old or older age group. Risk of specific TEAEs was numerically higher in patients aged 65 years or older treated with abrocitinib 200 mg and underscores the importance of dose selection in older patients.
Authors
- Jonathan I. Silverberg (ORCID: https://orcid.org/0000-0003-3686-7805)
- Eric L. Simpson (ORCID: https://orcid.org/0000-0003-0853-0252)
- Michael J. Cork (ORCID: https://orcid.org/0000-0003-4428-2428)
- Mette Deleuran (ORCID: https://orcid.org/0000-0003-0593-9925)
- Justine Alderfer (ORCID: https://orcid.org/0000-0003-3006-1675)
- Linda Stein Gold (ORCID: https://orcid.org/0000-0002-2758-1605)
- William Romero (ORCID: https://orcid.org/0000-0002-5573-0110)
- Alan D. Irvine (ORCID: https://orcid.org/0000-0002-9048-2044)
- Hernán Valdez (ORCID: https://orcid.org/0000-0001-8058-1922)
- Haiyun Fan
- Bob Geng
Institutions
- Henry Ford Health System (US)
- Oregon Health & Science University (US)
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- George Washington University (US)
- Trinity College Dublin (IE)
- UC San Diego Health System (US)
- Aarhus University Hospital (DK)
- Sheffield Children's Hospital (GB)
- University of Sheffield (GB)
Publication Details
- Journal
- The Journal of Allergy and Clinical Immunology In Practice
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1016/j.jaip.2025.02.040
- Citations
- 9
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 18.04